Zebertavage, L.; Schopf, A.; Nielsen, M.; Matthews, J.; Erbe, A.K.; Aiken, T.J.; Katz, S.; Sun, C.; Witt, C.M.; Rakhmilevich, A.L.;
et al. Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy. J. Clin. Med. 2024, 13, 2561.
https://doi.org/10.3390/jcm13092561
AMA Style
Zebertavage L, Schopf A, Nielsen M, Matthews J, Erbe AK, Aiken TJ, Katz S, Sun C, Witt CM, Rakhmilevich AL,
et al. Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy. Journal of Clinical Medicine. 2024; 13(9):2561.
https://doi.org/10.3390/jcm13092561
Chicago/Turabian Style
Zebertavage, Lauren, Allison Schopf, Megan Nielsen, Joel Matthews, Amy K. Erbe, Taylor J. Aiken, Sydney Katz, Claire Sun, Cole M. Witt, Alexander L. Rakhmilevich,
and et al. 2024. "Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy" Journal of Clinical Medicine 13, no. 9: 2561.
https://doi.org/10.3390/jcm13092561
APA Style
Zebertavage, L., Schopf, A., Nielsen, M., Matthews, J., Erbe, A. K., Aiken, T. J., Katz, S., Sun, C., Witt, C. M., Rakhmilevich, A. L., & Sondel, P. M.
(2024). Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy. Journal of Clinical Medicine, 13(9), 2561.
https://doi.org/10.3390/jcm13092561
